Search Results - "Bradley-Garelik, M. Brigid" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

$Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study$

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

by Lesokhin, Alexander M, Ansell, Stephen M, Armand, Philippe, Scott, Emma C, Halwani, Ahmad, Gutierrez, Martin, Millenson, Michael M, Cohen, Adam D, Schuster, Stephen J, Lebovic, Daniel, Dhodapkar, Madhav, Avigan, David, Chapuy, Bjoern, Ligon, Azra H, Freeman, Gordon J, Rodig, Scott J, Cattry, Deepika, Zhu, Lili, Grosso, Joseph F, Bradley Garelik, M Brigid, Shipp, Margaret A, Borrello, Ivan, Timmerman, John
Published in Journal of clinical oncology (10.08.2016)

Get full text

Journal Article

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

by Kantarjian, Hagop M., Shah, Neil P., Cortes, Jorge E., Baccarani, Michele, Agarwal, Mohan B., Undurraga, María Soledad, Wang, Jianxiang, Kassack Ipiña, Juan Julio, Kim, Dong-Wook, Ogura, Michinori, Pavlovsky, Carolina, Junghanss, Christian, Milone, Jorge H., Nicolini, Franck E., Robak, Tadeusz, Van Droogenbroeck, Jan, Vellenga, Edo, Bradley-Garelik, M. Brigid, Zhu, Chao, Hochhaus, Andreas
Published in Blood (02.02.2012)

Get full text

Journal Article

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

by Kantarjian, Hagop, Shah, Neil P, Shah, Sandip, Hochhaus, Andreas, Cortes, Jorge, Ayala, Manuel, Moiraghi, Beatriz, Shen, Zhixiang, Mayer, Jiri, Pasquini, Ricardo, Nakamae, Hirohisa, Huguet, Françoise, Boqué, Concepción, Chuah, Charles, Bleickardt, Eric, Bradley-Garelik, M. Brigid, Zhu, Chao, Szatrowski, Ted, Shapiro, David, Baccarani, Michele
Published in The New England journal of medicine (17.06.2010)

Get full text

Journal Article

Dasatinib in Imatinib- Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia in Blast Phase After 2 Years of Follow-Up in a Phase 3 Study: Efficacy and Tolerability of 140 Milligrams Once Daily and 70 Milligrams Twice Daily

Dasatinib in Imatinib- Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia in Blast Phase After 2 Years of Follow-Up in a Phase 3 Study: Efficacy and Tolerability of 140 Milligrams Once Daily and 70 Milligrams Twice Daily

by SAGLIO, Giuseppe, HOCHHAUS, Andreas, CHAO ZHU, DOMBRET, Herve, YEOW TEE GOH, MASSZI, Tamas, PASQUINI, Ricardo, MALOISEL, Frederic, ERBEN, Philipp, CORTES, Jorge, PAQUETTE, Ronald, BRADLEY-GARELIK, M. Brigid
Published in Cancer (15.08.2010)

Get full text

Journal Article

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

by Kantarjian, Hagop, Cortes, Jorge, Kim, Dong-Wook, Dorlhiac-Llacer, Pedro, Pasquini, Ricardo, DiPersio, John, Müller, Martin C., Radich, Jerald P., Khoury, H. Jean, Khoroshko, Nina, Bradley-Garelik, M. Brigid, Zhu, Chao, Tallman, Martin S.
Published in Blood (18.06.2009)

Get full text

Journal Article

Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia

by Kim, Dong-Wook, Goh, Yeow-Tee, Hsiao, Hui-Hua, Caguioa, Priscilla B., Kim, Dongho, Kim, Wan-Seok, Saikia, Tapan, Agrawal, Shruti, Roy, Amit, Dai, David, Bradley-Garelik, M. Brigid, Mukhopadhyay, Jaydip, Jootar, Saengsuree
Published in International journal of hematology (01.06.2009)

Get full text

Journal Article

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase

by Chuah, Charles T., Nakamae, Hirohisa, Shen, Zhixiang X., Bradley-Garelik, M. Brigid, Kim, Dong-Wook
Published in Leukemia & lymphoma (01.09.2014)

Get full text

Journal Article

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

by Jabbour, Elias, Kantarjian, Hagop M., Saglio, Giuseppe, Steegmann, Juan Luis, Shah, Neil P., Boqué, Concepción, Chuah, Charles, Pavlovsky, Carolina, Mayer, Jiří, Cortes, Jorge, Baccarani, Michele, Kim, Dong-Wook, Bradley-Garelik, M. Brigid, Mohamed, Hesham, Wildgust, Mark, Hochhaus, Andreas
Published in Blood (23.01.2014)

Get full text

Journal Article

Cross-Intolerance with Dasatinib Among Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia

Cross-Intolerance with Dasatinib Among Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia

by Khoury, Hanna J, Goldberg, Stuart L, Mauro, Michael J, Stone, Richard M, Deininger, Michael W, Bradley-Garelik, M. Brigid, Mohamed, Hesham, Guilhot, François
Published in Clinical lymphoma, myeloma and leukemia (01.06.2016)

Get full text

Journal Article

Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study

Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study

by Saglio, Giuseppe, Hochhaus, Andreas, Goh, Yeow Tee, Masszi, Tamas, Pasquini, Ricardo, Maloisel, Frederic, Erben, Philipp, Cortes, Jorge, Paquette, Ronald, Bradley‐Garelik, M. Brigid, Zhu, Chao, Dombret, Herve
Published in Cancer (15.08.2010)

Get full text

Journal Article

$Abstract 2044: Pharmacokinetics (PK) of nivolumab in patients with relapsed or refractory lymphoid malignancies$

Abstract 2044: Pharmacokinetics (PK) of nivolumab in patients with relapsed or refractory lymphoid malignancies

by Wang, Xiaoli, Hruska, Matthew, Bradley-Garelik, M. Brigid, Boone, Bradly, Bello, Akintunde
Published in Cancer research (Chicago, Ill.) (15.07.2016)

Get full text

Journal Article

$Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039)$

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039)

by Ansell, Stephen, Armand, Philippe, Timmerman, John M., Shipp, Margaret A., Bradley Garelik, M Brigid, Zhu, Lili, Lesokhin, Alexander M.
Published in Blood (03.12.2015)

Get full text

Journal Article

Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response

Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response

by Cortes, Jorge E., Hochhaus, Andreas, Kim, Dong-Wook, Shah, Neil P., Mayer, Jiri, Rowlings, Philip, Nakamae, Hirohisa, Bradley-Garelik, M. Brigid, Mohamed, Hesham, Kantarjian, Hagop M., Saglio, Giuseppe
Published in Blood (15.11.2013)

Get full text

Journal Article

Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up

Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up

by Hochhaus, Andreas, Shah, Neil P., Cortes, Jorge E., Baccarani, Michele, Bradley-Garelik, M. Brigid, Dejardin, David, Kantarjian, Hagop
Published in Journal of clinical oncology (20.05.2012)

Get full text

Journal Article

A phase II study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) or Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to imatinib

A phase II study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) or Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to imatinib

by Zwaan, Michel, Stork, Linda C., Bertrand, Yves, Gore, Lia, Hijiya, Nobuko, De Souza, Carmino, de Martino Lee, Maria Lucia, Bradley-Garelik, M. Brigid, Kearns, Pamela
Published in Journal of clinical oncology (20.05.2012)

Get full text

Journal Article

Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial

Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial

by Saglio, Giuseppe, Hochhaus, Andreas, Cortes, Jorge E., Kantarjian, Hagop, Baccarani, Michele, Bradley-Garelik, M. Brigid, Dejardin, David, Shah, Neil P.
Published in Blood (19.11.2010)

Get full text

Journal Article

Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up

Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up

by Shah, Neil, Kantarjian, Hagop, Hochhaus, Andreas, Cortes, Jorge E., Bradley-Garelik, M. Brigid, Zhu, Chao, Baccarani, Michele
Published in Blood (19.11.2010)

Get full text

Journal Article

Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial

Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial

by Guilhot, Francois, Kantarjian, Hagop, Shah, Neil P., Hochhaus, Andreas, Bradley-Garelik, M. Brigid, Dejardin, David, Cortes, Jorge E.
Published in Blood (19.11.2010)

Get full text

Journal Article

Occurrence, Management, and Outcomes In Patients with Pleural Effusion During Dasatinib Treatment for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) In the First-Line Setting: Analysis of the DASISION Trial

Occurrence, Management, and Outcomes In Patients with Pleural Effusion During Dasatinib Treatment for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) In the First-Line Setting: Analysis of the DASISION Trial

by Porkka, Kimmo, Baccarani, Michele, Hochhaus, Andreas, Kantarjian, Hagop, Mustjoki, Satu, Bradley-Garelik, M. Brigid, Zhu, Chao, Cortes, Jorge E.
Published in Blood (19.11.2010)

Get full text

Journal Article

Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial

Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial

by Khoury, H. Jean, Cortes, Jorge E., Kantarjian, Hagop, Baccarani, Michele, Shah, Neil P., Bradley-Garelik, M. Brigid, Dejardin, David, Hochhaus, Andreas
Published in Blood (19.11.2010)

Get full text

Journal Article